EP2262809A1 - Hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liés à la benzophénone-pipérazine en tant qu'agents anti-cancéreux potentiels et procédé d'obtention des ces hybrides - Google Patents

Hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liés à la benzophénone-pipérazine en tant qu'agents anti-cancéreux potentiels et procédé d'obtention des ces hybrides

Info

Publication number
EP2262809A1
EP2262809A1 EP08873530A EP08873530A EP2262809A1 EP 2262809 A1 EP2262809 A1 EP 2262809A1 EP 08873530 A EP08873530 A EP 08873530A EP 08873530 A EP08873530 A EP 08873530A EP 2262809 A1 EP2262809 A1 EP 2262809A1
Authority
EP
European Patent Office
Prior art keywords
benzodiazepine
pyrrolo
benzophenone
methoxy
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08873530A
Other languages
German (de)
English (en)
Inventor
Ahmed Kamal
Bandari Rajendra Prasad
Adla Malla Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research CSIR
Original Assignee
Council of Scientific and Industrial Research CSIR
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research CSIR filed Critical Council of Scientific and Industrial Research CSIR
Publication of EP2262809A1 publication Critical patent/EP2262809A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to benzophenone-piperazine linked pyrrolo[2,1- c][1 , ⁇ benzodiazepine hybrids and a process for the preparation there of. More particularly It relates to 7-Methoxy-8-[n- ⁇ /1 -[4-chloro-2-(2-chlorobenzoyl)phenyl]-2-piperazino-acetamide] alkyloxy ⁇ -(11 aS)-1 ,2,3, 11 a-tetrahydro-5H-pyrrolo[2, 1 -c][1 ,4] benzodiazepine-5-one with aliphatic chain length variations useful as anticancer (antitumour) agent.
  • the structural formula of these benzophenone-piperazine linked pyrrolo[2,1-c][1,4]benzodiazepines hybrids is given below.
  • Pyrrolo[2,1-c][1 ,4]benzodiazepine antitumour antibiotics are commonly known as anthramycin class of compounds.
  • PBDs pyrrolo [2, 1-c][1 ⁇ benzodiazepines
  • antibiotics react covalently with DNA to form an N2-guanine adduct that lies within the minor groove of duplex DNA via an acid-labile aminal bond to the electrophilic imine at the N10-C11 position
  • PBD dimers have been developed that comprise of two C2-exo-methylene substituted DC-81 subunits tethered through their C-8 position via an inert propanedioxy linker (Gregson, S. J.; Howard, P. W.; Hartely, J. A.; Brooks, N. A.; Adams, L. J.; Jenkins, T. C; Kelland, L R. and Thurston, D. E. J. Med. Chem. 2001, 44, 737).
  • a non-cross-linking mixed imine-amide PBD dimers have been synthesized that have significant DNA binding ability and potent antitumour activity (Kamal, A.; Ramesh, G.
  • Naturally occurring pyrrolo[2,1-c][1 , ⁇ benzodiazepines belong to a group of antitumour antibiotics derived from Streptomyces species. Recently, there is much impetus for the PBD systems as they can recognize and bind to specific sequence of DNA. Examples of naturally occurring PBDs include anthramycin, DC-81 , tomaymycin, sibiromycin and neothramycin.
  • the main objective of the present invention is to provide novel benzophenone - piperazine linked pyrrolo[2,1-c][1 , ⁇ benzodiazepine hybrids, useful as antitumour agents.
  • Yet another object of this invention is to provide a process for the preparation of novel benzophenone-piperazine linked pyrrolo[2,1-c][1 , ⁇ benzodiazepine hybrids.
  • the present invention provides a novel benzophenone-piperazine linked pyrrolo[2,1-c][1 , ⁇ benzodiazepine hybrid of general formula 5
  • n 3, 4, 5, 6, 8
  • novel benzophenone-piperazine linked pyrrolo[2,1-c][1 , ⁇ benzodiazepine hybrid according to claim 1 is represented by the group of the following compounds:
  • novel benzophenone-piperazine linked pyrrolo [2,1- c][1 ,4]benzodiazepine hybrid exhibits an in vitro anticancer/antitumour activity against human cancer cell lines selected from the group consisting of lung (Hop-62), cervix (SiHa), breast (MCF7, Zr-75-1), colon (Colo205), prostate (DU 145, PC3) and oral (DWD, HT1080) cell lines.
  • the concentration of benzophenone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrid used for in vitro activity against Colo205 for IC50 is in the range of 13 to 80 ⁇ m, at an exposure period of at least 48 hrs.
  • the concentration of benzophenone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against DU145 for IC50 is in the range of 12 to 80 ⁇ m, at an exposure period of at least 48 hrs.
  • the concentration of benzophenone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against DWD for IC50 is in the range of 8 to 80 ⁇ m, at an exposure period of at least 48 hrs. In yet another embodiment the concentration of benzophenone linked pyrrolo[2,1- c][1 , ⁇ benzodiazepine hybrids used for in vitro activity against HoP62 for IC50 is in the range of 11 to 48 ⁇ m, at an exposure period of at least 48 hrs.
  • the concentration of benzophenone linked pyrrolo[2,1- c][1,4]benzodiazepine hybrids used for in vitro activity against HT1080 for IC50 is in the range of 14 to 36 ⁇ m, at an exposure period of at least 48 hrs.
  • the concentration of benzophenone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against MCF7 for IC50 is in the range of 22 to about 80 ⁇ m, at an exposure period of at least 48 hrs.
  • the concentration of benzophenone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against PC3 for IC50 is in the range of 28 to about 80 ⁇ m, at an exposure period of at least 48 hrs.
  • the concentration of benzophenone linked pyrrolo[2,1- c][1,4]benzodiazepine hybrids used for in vitro activity against SiHa for IC50 is in the range of 36 to about 80 ⁇ m, at an exposure period of at least 48 hrs.
  • the concentration of benzophenone linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrids used for in vitro activity against Zr-75-1 for IC50 is in the range of 29 to about 80 ⁇ m, at an exposure period of at least 48 hrs.
  • the present invention further provides a pharmaceutical composition
  • a pharmaceutical composition comprising benzophenone linked pyrrolo[2,1-c][1 ,4]benzodiazepine hybrid, its derivatives, analogues, salts or mixture thereof optionally with pharmaceutically acceptable carriers, adjuvants and additives.
  • benzophenone-piperazine linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrid used is represented by a general formula 5,
  • n 3, 4, 5, 6, 8 and the said process comprising the steps of: a) reacting (2S)-N-[(n-bromoalkyloxy)-3-methoxy-2-nitrobenzoyl)]pyrrolidine-2- carboxaldehyde diethylthioacetal of formula 1
  • n 3, 4, 5, 6, 8 4a-e c) reacting the above said amino compound of formula 4 obtained in step (b) with a deprotecting agent of the kind of mercuric chloride by known method to obtain the desired compound of formula 5
  • the mild inorganic base used in steps (a) is potassium carbonate.
  • aprotic organic solvent used in step (a) is acetone and acetonitrile
  • organic solvent used in step (c) is acetonitrile and acetone
  • the alcohol used in step (b) is selected from methanol and ethanol.
  • the compounds of formula 5a-e obtained are represented by a group of the following compounds:
  • the benzophenone-piperazine linked pyrrolo[2,1- c][1 ,4]benzodiazepine hybrid of formula 5a-e exhibits an in vitro anticancer/antitumour activity against human cancer cell lines selected from the group consisting of lung, cervix, breast, colon, prostate and oral cell lines.
  • Reagents and conditions (i) K 2 CO 3 , acetone,18 h, refllux, 90-92%; (ii) SnCI 2 .2H 2 O, MeOH, 2 h, reflux, 8! 87%; (iii) HgCI 2 -CaCO 3 , CH 3 CN-H 2 O (4:1), 12 h, rt, 68-71 %.
  • This compound was prepared according to the method described for the compound 3 a by employing 2S- ⁇ /-[4-(4-bromobutoxy)-5-methoxy-2-nitrobenzoyl] pyrrolidine-2- carboxaldehyde (1b) diethylthioacetal (535 mg, 1.0 mmol) was added anhydrous potassium carbonate (690 mg, 5.0 mmol) and ⁇ /1-4-chloro-2-(2-chlorobenzoyl)phenyl]-2- piperazinoacetamide 2 (392 mg, 1.0 mmol) to obtain the pure product 3b (710 mg, 84% yield).
  • This compound was prepared according to the method described for the compound 4a by reducing 2S- ⁇ /- ⁇ 4-[4- ⁇ /1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-2-piperazinoacetamide] butyl)oxy-5-methoxy-2-nitrobenzoyl ⁇ pyrrolidine-2-carboxaldehyde diethylthioacetal 3b (846 mg, 1.0 mmol) using SnCI 2 .2H 2 O (1.12 g, 5.0 mmol). The amino compound 4b obtained was (795 mg, 97% yield).
  • This compound was prepared according to the method described for the compound 5a employing 2S- ⁇ /-4- ⁇ /1 -[4-chloro-2-(2-chlorobenzoyl)phenyl]-2-piperazinoacetamide]butyl) oxy-5-methoxy-2-aminobenzoyl ⁇ pyrrolidine-2-carboxaldehyde diethylthioacetal 4b (816 mg, 1.0 mmol) and HgCI 2 (582 mg, 2.26 mmol), CaCO 3 (230 mg, 2.46 mmol) in acetonitrile-water (4: 1) to obtain the pure product 5b (330 mg, 58% yield).).
  • This compound was prepared according to the method described for the compound 3a by employing 2S- ⁇ /-[4-(5-bromopenyloxy)-5-methoxy-2-nitrobenzoyl] pyrrolidine-2- carboxaldehyde diethylthioacetal (1c) (549 mg, 1.0 mmol) was added anhydrous potassium carbonate (690 mg, 5.0 mmol) and ⁇ /1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-2- piperazinoacetamide 2 (392 mg, 1.0 mmol) to obtain the pure product 3c (740 mg, 87% yield).
  • This compound was prepared according to the method described for the compound 5a employing 2S- ⁇ /-[5- ⁇ /1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-2-piperazinoacetamide] pentyl)oxy-5-methoxy-2-aminobenzoyl ⁇ pyrrolidine-2-carboxaldehyde diethylthioacetal 4c (830 mg, 1.0 mmol) and HgCI 2 (590 mg, 2.26 mmol), CaCO 3 (244 mg, 2.46 mmol) in acetonitrile-water (4:1) to obtain the pure product 5c (330 mg, 58% yield).
  • This compound was prepared according to the method described for the compound 3a by employing 2S- ⁇ /-[4-(6-bromohexyloxy)-5-methoxy-2-nitrobenzoyl]pyrrolidine-2- carboxaldehyde diethylthioacetal 1d (563 mg, 1.0 mmol) was added anhydrous potassium carbonate (690 mg, 5.0 mmol) and ⁇ /1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-2- piperazinoacetamide 2 (392 mg,1.0 mmol) to obtain the pure product (3d) (775 mg, 88% yield).
  • This compound was prepared according to the method described for the compound 4a by reducing 2S- ⁇ // ' 4-/6- ⁇ /1-[4-chloro-2-(2-chlorobenzoyl)phenyl]-2-piperazinoacetamide] hexyl)oxy-5-methoxy-2-nitrobenzoyl ⁇ pyrrolidine-2-carboxaldehyde diethyl thioacetal 3d (874 mg, 1.0 mmol) using SnCI 2 .2H 2 O (1.12 g, 5.0 mol). The amino compound 4d obtained was (842 mg, 97% yield).
  • the C8-linked benzophenone-piperazine-PBD hybrids have been tested against sixty human tumour cell lines derived from nine cancer types (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer) as per NCI protocol.
  • dose response curves for individual cell lines have been measured at a minimum of five concentrations at 10 fold dilutions.
  • a protocol of 48 h continuous drug exposure has been used, and a sulforhodamine B (SRB) protein assay was used to estimate cell viability or growth.
  • the concentration for 50% cell growth inhibition (Gl 50 ), total cell growth inhibition (TGI, 0% growth) and 50% cell death (LC 50 , 50% growth) compared with the control has been calculated (Figure-2).
  • Compounds 5b and 5d have been evaluated for their in vitro cytotoxicity in eleven cell lines from nine human cancer cell lines of colon (Colo205), lung (Hop-62), cervix (SiHa), prostate (DU145, PC3), oral (DWD, HT1080), and breast (MCF7, Zr-75-1) origin. The results are expressed as percent of cell growth determined relative to that of untreated control cells (Table 1). The representative compounds 5b and 5d have shown significant cytotoxicity against some cancer cell lines.
  • Each cancer type represents the average of six to eight different cancer cell lines.
  • 5b-d exhibits a wide spectrum of activity against fifty six cell lines in nine cell panels, with Gl 50 value of ⁇ 20 nM.
  • the growth of HOP-62, NCI-H23 cell lines were affected by compound 5b with Gl 50 values as 20.1 , 24.2 and 27.1 nM respectively.
  • the Gl 50 values of compound 5d against colon cancer HCC-2988, HCT-116 and KM12 cell lines are 21.3, 21.8 and 23.7 nM respectively.
  • the Gl 50 values for compound 5b against CNS SF-295, SF-539, SNB-19 and SNB-75 cell lines are in a range of 14.1-33.5 nM.
  • Compound 5b exhibits activity against fifty-six cell lines in nine cancer cell panels with Gl 50 values of ⁇ 10 ⁇ M.
  • Compound 5d exhibits activity against fifty-seven cell lines in nine cancer cell panels, Gl 50 values of ⁇ 10 ⁇ M.
  • In vitro cytotoxicity of compounds 5b and 5d in selected cancer cell lines has been illustrated in Table 2.
  • the average Gl 50 values for each cancer panel of compounds 5b and 5d have been illustrated in Table 3.
  • the mean graph mid point values of Iog 10 TGI and log 10 LC 50 as well as log 10 Gl 50 for 5b and 5d are listed in Table-1. As demonstrated by mean graph pattern, compounds 5b and 5d exhibit an interesting profile of activity and selectivity for various cell lines.
  • the mean graph mid points of log-io TGI and log 10 LCg 0 have shown similar pattern to the logTM Gl 50 mean graph mid points.
  • Table-3. log 10 Gl 50 , logioTGI and log 10 LC 50 mean graphs midpoints(MG_MID) of in vitro cytotoxicity data for the compounds 5b and 5d against human tumour cell lines.
  • Thermal denaturation studies Compounds have been subjected to thermal denaturation studies with duplex-form calf thymus DNA (CT-DNA) using a modification of a reported procedure.
  • Working solutions in aqueous buffer (10 mM NaH 2 PO 4 ZNa 2 HPO 4 , 1 mM Na 2 EDTA, pH 7.00 + 0.01) containing CT-DNA (100 nm in phosphate) and the PBD (20nm) have been prepared by addition of concentrated PBD solutions in DMSO to obtain a fixed [PBD]/[DNA] molar ratio of 1:5.
  • the DNA-PBD solutions have been incubated at 37 0 C for 0 and 18 h prior to analysis.
  • the present invention provides novel pyrrolo[2,1-c][1 , ⁇ benzodiazepine hybrids useful as antitumour agents. ;
  • novel C8-linked benzophenone-piperazine-PBD hybrids that have been synthesized exhibited significant DNA-binding ability and showed cytotoxic activity against sixty human tumour cell lines. Some of these hybrids exhibited promising DNA-binding among these hybrids the compound 5c show high DNA-binding ability (9.6 0 C).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liés à la benzophénone-pipérazine représentés par la formule générale 5a-e, convenant comme agents anti-tumeurs potentiels contre des lignées de cellules cancéreuses humaines. Est décrit un procédé de fabrication de d'hybrides de pyrrolo[2,1-c][1, 4]benzodiazépine représentés par les formules (5a-e).
EP08873530A 2008-03-26 2008-10-31 Hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liés à la benzophénone-pipérazine en tant qu'agents anti-cancéreux potentiels et procédé d'obtention des ces hybrides Withdrawn EP2262809A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN787DE2008 2008-03-26
PCT/IN2008/000714 WO2009118749A1 (fr) 2008-03-26 2008-10-31 Hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liés à la benzophénone-pipérazine en tant qu'agents anti-cancéreux potentiels et procédé d'obtention des ces hybrides

Publications (1)

Publication Number Publication Date
EP2262809A1 true EP2262809A1 (fr) 2010-12-22

Family

ID=40344419

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08873530A Withdrawn EP2262809A1 (fr) 2008-03-26 2008-10-31 Hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liés à la benzophénone-pipérazine en tant qu'agents anti-cancéreux potentiels et procédé d'obtention des ces hybrides

Country Status (3)

Country Link
EP (1) EP2262809A1 (fr)
JP (1) JP2011515459A (fr)
WO (1) WO2009118749A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608663B1 (fr) * 2003-03-31 2008-11-05 Council of Scientific and Industrial Research Dimeres de pyrrolo(2,1-c) (1,4) benzodiazepine en tant qu'agents antitumoraux et procede correspondant
JP4638485B2 (ja) * 2004-06-30 2011-02-23 カウンシル オブ サイエンティフィク アンド インダストリアル リサーチ ピペラジン部分により結合したピロロ［２，１−ｃ］［１，４］ベンゾジアゼピン−ナフタルイミド結合体及びそれを調製するための方法
DE112005003752T5 (de) * 2005-11-10 2008-11-13 Council Of Scientific & Industrial Research Neues Pyrrolo[2,1-c][1,4]benzodiapezinhybrid und ein Verfahren zu dessen Herstellung
CA2660799C (fr) * 2006-08-14 2013-03-19 Council Of Scientific & Industrial Research Hybrides pyrrolo[2,1-c][1,4]benzodiazepine et leur procede de preparation
WO2008120235A1 (fr) * 2007-03-30 2008-10-09 Council Of Scientific & Industrial Research Nouveaux hybrides de benzophénone utilisés comme agents anticancéreux potentiels et procédé de préparation de ceux-ci

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2009118749A1 *

Also Published As

Publication number Publication date
JP2011515459A (ja) 2011-05-19
WO2009118749A1 (fr) 2009-10-01

Similar Documents

Publication Publication Date Title
EP2061795B1 (fr) Hybrides pyrrolo[2,1-c][1,4]benzodiazépine et leur procédé de préparation
CA2520898C (fr) Pyrrolo(2,1-c)(1,4)benzodiazepines non-reticulees comme agents anticancereux potentiels et leur procede de preparation
US8927538B2 (en) Carbazole linked pyrrolo[2,1-c][1,4]benzodiazefine hybrids as potential anticancer agents and process for the preparation thereof
US8153627B2 (en) Quinazoline linked pyrrolo[2,1-C][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
US20050222132A1 (en) C8 - linked pyrrolo[2,1-c][1,4]benzodiazepine-acridone/acridine hybrids
US7015215B2 (en) Pyrrolo[2,1-c][1,4] benzodiazepines compounds and process thereof
WO2009118749A1 (fr) Hybrides de pyrrolo[2,1-c][1,4]benzodiazépine liés à la benzophénone-pipérazine en tant qu'agents anti-cancéreux potentiels et procédé d'obtention des ces hybrides
US8461150B2 (en) Chalcone linked pyrrolo[2,1-c][1, 4]benzodiazepine hybrids as potential anticancer agents and process for the preparation thereof
US8722665B2 (en) Cinnamido-pyrrolo[2,1-C][1,4]benzodiazepines as potential anticancer agents and process for the preparation thereof
EP2271648B1 (fr) Hybrides de pyrrolo [2,1-c][1,4]benzodiazépine liés à l'isoxazoline en tant qu'agents anti-cancéreux potentiels et leurs procédés de fabrication
WO2004087711A1 (fr) Derives de pyrrolo (2,1-c) (1,4) benzodiazepine lies au pyrene utiles en tant qu'agents anticancereux
US6683073B1 (en) Pyrimidine linked pyrrolo[2,1-c][1,4]benzodiazepines as potential antitumour agents
EP2350085B1 (fr) Hybrides de pyrrolo[2,1-c][1.4]benzodiazépine liée à la quinazolinone en tant qu'agents anticancéreux potentiels et leur procédé de préparation
WO2005063760A1 (fr) Hybrides acridone/acridine de pyrrolo[2,1-c][1,4]benzodiazepine a liaison c-8
EP2648757B1 (fr) Conjugués d'imidazo[1,5-a]pyridine liés à la pyrrolo[2,1-c][1,4]benzodiazépine comme agents antitumoraux potentiels, et procédé de préparation de ceux-ci
WO2004087712A1 (fr) Nouvelles pyrrolo[2,1-c][1,4]benzodiazepines a liaison pyrimidine utilisees comme agents antitumoraux potentiels
EP2294070B1 (fr) Nouveaux hybrides de phenanthrylphenol et pyrrolo[2,1-c][1,4]benzodiazepine en tant qu'antitumoraux potentiels et procede pour leur preparation
EP2271647A1 (fr) Dimères de pyrrolo[2,1-c][1,4] benzodiazépine liés un cycle pipérazine substitués par c2-fluoré et son procédé de préparation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20111202

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120613